DexCom 3rd-quarter loss widened on higher costs

DexCom posted a net loss of $14.7 million, or 50 cents per share, compared with a net loss of $11.4 million, or 40 cents per share, in the year-earlier period.

Revenue climbed 57 percent to $1.9 million from $1.2 million.

The latest results included $2.7 million in expenses, largely from share-based compensation.

Analysts polled by Thomson Reuters had expected a loss of 46 cents per share on revenue of $2.5 million. Analysts typically exclude items.

DexCom, which makes medical devices for diabetic people, said cost of sales rose to $3.8 million from $3.1 million a year ago due to higher sales and product development costs.

Higher general and administrative costs also drove up overall expenses, the company said.

DexCom shares rose 5 cents to $3.63 in aftermarket trading after closing during the regular session at $3.58, down 19 cents, or 5 percent.